Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Added at 9.33. This is just a knee jerk reaction, and I bet we recover a lot of this before the close.
The market just yawned over this...
This stock has been rock solid since earnings, and over many down days.
I was thinking the exact same thing. Good sign on sentiment towards BAC.
I think it's just a matter of time before they get a sizable foundry deal done. I love the idea of Cisco because there are no marketing "conflicts" to deal with versus Apple. Though Apple would be huge...
Intel rises on Apple foundry speculation
http://www.marketwatch.com/story/intel-rises-on-apple-foundry-speculation-2012-10-16?siteid=nbsh
Amazon wants to be a player...
http://www.marketwatch.com/story/amazon-said-in-talks-to-buy-ti-mobile-chip-lines-2012-10-15?siteid=nbsh
I don't think anyone is pricing in foundry revenue. Based on past clues from management that 22nm yield has been better than expected, a lot of capacity at 22 in case the yield wasn't, and then coupled with the fact that companies are probably beating the door down at Intel to get some of it since the process is slow/failing elsewhere. I think if is just a matter of time until we get a Cisco foundry deal or something close. Throw a billion in revenues on top of what we have today, a ramp up in demand due to windows 8 that we saw reported signs of last week, and the fact that we're technically oversold; nice combo for a pop.
Just food for thought.
Options Markets Sees Bank of America Popping Back Over $10
http://blogs.wsj.com/marketbeat/2012/10/01/options-markets-sees-bank-of-america-popping-back-over-10/
Ask and ye shall receive...at least a PT lift. I agree, with more likely to come.
12:25 PM Nomura lifts its price target for GE (GE +0.2%) from $22 to $25 following yesterday's analyst day, seeing potential for value creation by GE further shrinking GE Capital as a percentage of the company. The firm sees industrial margin improvement as a positive driver as the ramp in R&D crests and simplification results in lower costs.
New Multi-Year High for GE From Infrastructure Forecast
Posted: September 27, 2012 at 2:47 pm
General Electric Co. (NYSE: GE) has been enjoying a recovery despite what has been a period of caution for so many global corporations. In a meeting today, GE’s Chairman and CEO Jeff Immelt has been talking up GE’s prospects going forward. Today’s presentation is from the GE Infrastructure Investor Meeting.
After having unveiled new mining initiatives earlier this week, Immelt has talked up the conglomerate’s industrial organic revenue growth to about 10% after a prior forecast of 5% to 10%. GE also signaled that it will record a gain of about three-cents per share in the third quarter period due to its prior stake sale of NBC-Universal.
Shares hit $22.69 today and that is not just a high for the last 52-weeks. This is a high going back to late in 2008 when GE was in free-fall along with just about every other company as the great recession was ripping apart America.
At today’s meeting the conglomerate is having presentations from executives in the following areas: Aviation, Oil & Gas, Healthcare, Energy Management, H&BS, Transportation, and Power & Water.
The entire slide show can be accessed here.
Our take is simple here. This is just one more supporting argument for why GE will raise its dividend at the end of this year for 2013.
JON C. OGG
Read more: New Multi-Year High for GE From Infrastructure Forecast - 24/7 Wall St. http://247wallst.com/2012/09/27/new-multi-year-high-for-ge-from-infrastructure-forecast/#ixzz27hTxtISV
I think support may be the 4% dividend yield level at 22.50, more than technical. Great yield, dividend should be safe, ride it out.
Nothing found. Hoping for drug partner.
Intel’s Clover Trail chip set to appear at Windows 8 tablet showcase on September 27
Intel has started inviting members of the press to what it’s calling a “showcase” of Intel-based Windows 8 tablets. The event will take place at the end of the month and the guest list is suitably illustrious, with executives from Acer, Asus, Samsung, Dell, HP, ZTE and Lenovo all expected to attend.
Read more: http://www.digitaltrends.com/mobile/intel-windows-8-showcase-clover-trail/#ixzz26vWtTH00
Low power, low power, and low power. Did I mention low power?
Clear what the hot button is now for Intel.
_______________________________________
Intel: Low-Power Processors to Fuel Future of Mobile Computing Innovation
Perceptual Computing to Reshape How People Interact with Devices
SAN FRANCISCO, Sep 11, 2012 (BUSINESS WIRE) -- --NEWS HIGHLIGHTS
--In 2013, 4th generation Intel(R) Core(TM) processor family based on "Haswell" microarchitecture will bring faster, thinner, lighter, cooler, more secure systems with built-in graphics to mainstream.
--New line of low-power processors drives power lower to inspire even more innovative Ultrabook(TM), convertible and tablet designs with the performance of "Haswell" microarchitecture.
--Intel Perceptual Computing Software Development Kit beta to help bring natural, intuitive experiences using gesture and voice interaction to Intel platforms.
Intel Corporation's chief product officer today described how its low-power processors, starting with the company's 4th generation Intel(R) Core(TM) processor family available next year, will set a new standard for mobile computing experiences and innovative Ultrabook(TM), convertible and tablet designs.
Speaking at the Intel Developer Forum in San Francisco, David (Dadi) Perlmutter said Intel reduced the platform idle power of its 4th generation Intel Core processor family based on the next-generation "Haswell" microarchitecture by more than 20 times over the 2nd generation while delivering outstanding performance and responsiveness. He also said Intel will add a new line of even lower-power processors based on the same microarchitecture to its roadmap starting in 2013.
Both new products underscore the company's focus to aggressively drive power consumption down to enable longer battery life and a wave of new, more mobile designs, while delivering ever-increasing processor, graphics and media performance.
"The 4th generation Intel Core processor family and our new line of low-power processors will usher in an era of unprecedented innovation in mobile computing," Perlmutter said. "Our focus to deliver even lower power with the great performance that our processors are known for is as fundamentally significant as when we shifted our development focus beyond sheer processor speed in 2001. As a result, you'll see our customers delivering sleek and cool convertible designs, as well as radical breakthrough experiences across a growing spectrum of mobile devices."
Intel Powers the Spectrum of Mobile Experiences, Convertible Designs
Since Intel created and invested in the ecosystem for the new category of Ultrabook systems last year, it has already inspired dramatic innovation in personal computing. More than 140 different Ultrabook designs are in development, a number of which are convertibles, with more than 70 powered by 3rd generation Intel Core processors available today.
When the company's 22nm 4th generation Intel Core processor family comes to the Ultrabook and other PCs in 2013, it will bring Intel HD graphics support, new instructions for faster encryption and performance, new hardware-based security features and low-power processor sub-states to enable longer battery life.
To spur even more innovation in mobile computing, Intel's new low-power chips based on "Haswell" microarchitecture will broaden the company's mobile roadmap, initially operating at about 10 watts to enable thinner, lighter Ultrabook, convertible and tablet designs with better performance and battery life.
Turning his attention to the full mobility spectrum, Perlmutter detailed how Intel delivers the best choices for every mobile experience. Coming soon, the next-generation Intel(R) Atom(TM) processor (codenamed "Clover Trail") is a new system-on-chip (SoC) architected specifically for Windows* 8. Based on Intel's 32nm process technology, it powers lightweight tablets and convertibles, and includes outstanding battery life and always-on technology in sleek designs.
Perlmutter also articulated the advantages of Intel-based Windows 8 devices, noting that Intel Atom- and Intel Core-based tablets and convertibles will deliver a range of new features from enhanced media capabilities, security built for enterprise vertical market solutions, and support for the breadth of applications written for Intel processors, thus retaining the software investment of IT and consumers.
"We believe Windows 8 on Intel(R) architecture will deliver the best experience, performance and compatibility across computing platforms," he said.
The Rise of Natural, Intuitive Computing Experiences
The personal computing experience is shifting to one based on perceptual computing where devices will take on human-like senses to perceive the user's intentions, according to Perlmutter, adding that Intel is driving these capabilities across Intel platforms both now and into the future.
Perlmutter invited the developer community to work with Intel to bring the next wave of perceptual computing capability to Intel Core-based platforms with the release of the company's first Intel Perceptual Computing Software Development Kit (SDK) beta. The SDK, targeted for release early next quarter, will enable hardware and software developers to bring gesture interaction, facial and voice recognition, and augmented reality to life on existing and future Intel Core processor-based Ultrabook systems and PCs.
Perlmutter talked about progress made to bring voice recognition to the Ultrabook while showing a system running the Nuance Dragon Assistant* Beta optimized for Intel Core processors. Dell plans to make the Dragon Assistant* Beta available in the United States next quarter in its Dell* XPS13 Ultrabook.
Intel INTC +1.29% is a world leader in computing innovation. The company designs and builds the essential technologies that serve as the foundation for the world's computing devices. Additional information about Intel is available at newsroom.intel.com and blogs.intel.com.
Intel, Ultrabook, Core, Atom and the Intel logo are trademarks of Intel Corporation in the United States and other countries. * Other names and brands may be claimed as the property of others.
SOURCE: Intel
I was wondering that, too...
Anyway, we can enjoy setting new 52 week highs while we wait.
A raise is being predicted...
Today's news may seem as though it is not that important because this $0.17 rate has been the same dividend payout for three consecutive quarters and that is prior to today's dividend declaration. We have maintained that General Electric will increase its dividend before the end of 2012 and if that is to occur it will now likely come in an announcement in early December.
http://www.dailyfinance.com/2012/09/07/ge-sticks-with-0-17-dividend-for-now/
General Electric (GE) declares $0.17/share quarterly dividend, in line with previous. Forward yield 3.17%. For shareholders of record Sep 24. Payable Oct 25. Ex-div date Sep 20
Aren't we overdue for the dividend announcement?
Thanks. Are you specifically saying 2580 and Clover Trail are two different things? I haven't seen that anywhere.
http://en.wikipedia.org/wiki/Atom_(system_on_chip)
Looks like they are trying a little better to communicate:
http://www.rexahn.com/cms/index.php/2012/09/rexahn-pharmaceuticals-provides-update-on-2012-strategic-goals/
• Active pursuit of new partnerships. Rexahn is in continuing dialogue with a range of potential partners, including out-licensing or co-development of the company’s promising oncology assets.
More speculation of Clover Trail launch with Moto.
I love this line...
It follows a recommendation by Deutsche Bank for investors to sell ARM shares “due to increased competition.”
http://www.gomonews.com/motorola-to-announce-intel-based-phone-in-next-few-days/
Good article explaining some of the phone launches over the next couple of weeks. The Verizon event is probably a qualcomm snapdragon. He speculates that the London event might include a higher performance variant of Medfield (Clover Trail?) If that were true, it would be the first port of Jelly Bean to Intel.
http://www.forbes.com/sites/patrickmoorhead/2012/09/03/motorola-and-intel-still-very-much-have-a-close-relationship/
So this will be a non-intel phone? I can't believe Verizon and Moto would wreck the Moto/Intel announcement on the 18th in London. LTE would mean Clover Trail if it was Intel? Very confusing...
Pre-market was exciting, but price swings happen due to lack of liquidity during those times. I admit, it looked good. We would be better off on a nice slow grind up, and keep the flippers out of it. Here's hoping.
We need more information on the results, their plans for the drug, etc. They need to be more forthcoming and talk; one of their weaknesses.
They have already applied for this drug for a phase II with ovarian.
Also, a phase III for Archexin and Pancreatic, but this will cost big bucks. They need a partner. Archexin may give them a shot at that.
Next, they should be launching a phase II for RX-3117. More milestone payments from Teva with that, so you know it is a priority.
Long long shot they are bought simply because they are so cheap. A lot of that going on by the big boys to fill the pipeline. It's pocket change to them at this level, and they may feel it is worth the gamble.
More waiting and watching.
Rexahn Pharmaceuticals Announces Positive Top-line Phase IIa Data for Archexin in Patients with Metastatic Pancreatic Cancer
ROCKVILLE, Md. --(Business Wire)--
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in oncology and CNS, today announced top-line results from a Phase II clinical study of Archexin®, its clinical-stage oncology drug candidate. Archexin is being developed as a potential first-in-class inhibitor of the Akt protein kinase (Akt) in cancer cells.
The open label 2-stage study was designed to assess the safety and efficacy of Archexin in combination with gemcitabine. Stage 1 was the dose finding portion and stage 2 was the dose expansion portion using the dose identified in stage 1 to be administered with gemcitabine. The study enrolled 31 subjects aged 18-65 years with metastatic pancreatic cancer at four centers in the United States and five centers in India. The primary endpoint was overall survival following 4 cycles of therapy with a 6-month follow-up.
For those evaluable patients according to the protocol, the study demonstrated that treatment with Archexin in combination with gemcitabine provided a median survival of 9.1 months compared to the historical survival data of 5.65 months (Burris et al., 1997, J. Clin Oncol 15:2403) for standard single agent gemcitabine therapy. The most frequently reported adverse events were constipation, nausea, abdominal pain, and pyrexia, regardless of relatedness.
Dr. Chang Ahn, Chief Executive Officer, Rexahn, said, "We are very pleased with the positive results of this early-stage clinical study to examine Archexin's profile as a potential Akt inhibitor of solid tumors. With this supportive clinical outcome data, we look forward to progressing the clinical development of this exciting compound."
Dr. Troy Guthrie, Baptist Medical Center in Jacksonville, FL, who was one f the investigators of the trial commented, "This study suggests that Archexin, in combination with gemcitabine, may be another treatment option for this difficult to treat cancer."
Read more: http://www.tmcnet.com/usubmit/2012/08/28/6540220.htm#ixzz24qHmpCJ7
Since an Intel phone has been in the wild for some time now, I thought it would be interesting to see how it is faring. I went to the Orange website for France, and looked at the phone reviews submitted by customers. It has an overall rating of 4.2 our of 5. What I was most interested in was compatibility with apps, and I didn't see this showing up as a problem; a very good sign. If you strip out some of the complaints that I would attribute to the older Android version, I would say that it is really doing well. No idea on sales levels, though. There are 29 reviews to look at.
I use Chrome which easily allows me to translate on the fly from French:
http://mobile-shop.orange.fr/telephone-portable/orange-avec-intel-inside
Short interest; with IDF coming, let's hope for some good announcements and a pop due to short covering. I would never be short before this event...
Intel Corp. (NASDAQ: INTC) rose 4% to 152.4 million shares in mid-August. This is the highest total in a year for Intel, and days to cover popped to 5.58. About 3% of Intel's float is now short.
Very positive review of Lenovo's new pad. (Atom)
The ThinkPad Tablet 2 is just 0.39 of an inch thick and weighs 1.3 pounds.
http://mashable.com/2012/08/08/lenovo-tablet-2/?source=email_rt_mc_body&ifp=0
Nice to break through the $21 wall.
Should get a bounce out of that one...
By the way, quarterly reports are reported after hours.
The only date for Archexin that I know about is the listed study completion data listed here (JULY.) With that, I would say they could release results any day now.
http://clinicaltrials.gov/ct2/show/NCT01028495?spons=%22Rexahn+Pharmaceuticals%2C+Inc.%22&spons_ex=Y&rank=4
I saw that but can't confirm either. Shot in the dark speculation...
Rexahn always releases their news at 8:00 AM on the dot via press release and puts in on their website simultaneously. Each to check each day.
Dividend declared.
SANTA CLARA, Calif., Jul 26, 2012 (BUSINESS WIRE) -- Intel Corporation's board of directors has declared a 22.5 cents per share (90 cents per share on an annual basis) quarterly dividend on the company's common stock. The dividend will be payable on Sept. 1, 2012 to stockholders of record on Aug. 7, 2012.
Elmer,
I am a bit confused...what was this?
http://www.bloomberg.com/news/2012-05-07/intel-increases-quarterly-dividend-to-22-5-cents-from-21-cents.html
I was really surprised on the recent action. Shows you that if there is action in a pharma stock, it attracts a lot of attention. Once the stock went up 20-40%, several others joined in on the action. It would be nice to know if pharma companies joined in that rally, since Rexahn is so cheap to buy. If they go over 5% they have to report it; so far that hasn't happened.
The press release that triggered this was nice, but the outcome of that new compound is so far off, that it can't be the only reason we rallied. I think it was a combination of the PR, and Archexin for Pancreatic being close to reporting its phase II results, with the latter being significant if positive. My thoughts are that the results will be positive because they just applied for Archexin for Ovarian cancer. I don't think they would have done that if the Pancreatic results were poor. They can't afford to do that because they are low on funds, and they have so many other compounds that they can promote. Plus, they made no mention of doing this in their "Goals for 2012" that they released months ago.
The Archexin for Pancreatic cancer results could be any day, since the study on the FDA site says July as the expected completion for all outcomes.
Yes, phase I results in 2012. That is the Teva partnership drug. They will fast track that one due to milestone payments. (RX-3117)
The study on Archexin is completing too.
http://clinicaltrials.gov/ct2/show/NCT01028495?spons=%22Rexahn+Pharmaceuticals%2C+Inc.%22&spons_ex=Y&rank=4
Tegra processor claimed...
First up is the most recent, sourced by Gizmodo, and shows a new image of the Nexus 7 tablet, which arrived with the following specs; 7-inch 1200 x 800 IPS display, 1.3GHz quad-core Tegra 3 processor, 1GB of RAM, 8GB or 16GB of internal storage, Android Jelly Bean, NFC and 1.2MP front-facing camera.
http://www.techradar.com/news/mobile-computing/tablets/google-nexus-7-release-date-news-and-rumours-1051918